Biochemical Engineering
Catalent Invests $100 Million to Expand European Biologics Manufacturing
23rd July 2021
Catalent has announced, in a July 21, 2021 press release, that it will start the first phase of a $100-million expansion program at its Italian facility in Anagni to increase its manufacturing capabilities for biologics drug substance. This first phase of the expansion will involve the installation of two 2000-L single-use bioreactors in new, purpose-built manufacturing suites. Additionally, early phase clinical development and late-stage and commercial tech transfers will be supported through associated investments. Infrastructure for a further six 2000-L single-use bioreactors will also be created in the initial phase. Source: Biopharm International 23/7/2021
Back to group news